Display Settings:

Format

Send to:

Choose Destination
    World J Surg. 2009 Apr;33(4):653-60.

    Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA).

    Source

    Michael E. DeBakey Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Molecular Surgeon Research Center, Baylor College of Medicine, One Baylor Plaza, Mail stop: BCM390, Houston, TX 77030, USA.

    Abstract

    Squamous cell carcinoma of the anus (SCCA) is a rare disease in the average population but is an increasing concern among immunocompromised individuals, such as the HIV-seropositive. Coinfection with human papillomavirus (HPV) in this population is common. HPV infection is difficult to clear with a compromised immune system, which results in a greater risk of tumor development and a more aggressive progression of the disease. The recent approval of a prophylactic HPV vaccine for cervical cancer has sparked an interest in a search for improved immunotherapeutic multimodality therapies to combat anogenital tumors associated with the virus. In this review, we discuss the known mechanisms of action of HIV-associated SCCA, examine the current treatments for the disease, and focus on the potential of an immunotherapeutic vaccine approach for both prophylactic and therapeutic application.

    PMID:
    19052810
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2924142
    Free PMC Article

      Supplemental Content

      Icon for Springer Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk